

Sara Ek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3060173/publications.pdf>

Version: 2024-02-01

45
papers

1,685
citations

331670

21
h-index

276875

41
g-index

47
all docs

47
docs citations

47
times ranked

2083
citing authors

#	ARTICLE	IF	CITATIONS
1	TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. <i>Blood</i> , 2017, 130, 1903-1910.	1.4	296
2	Nuclear expression of the non-B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. <i>Blood</i> , 2008, 111, 800-805.	1.4	185
3	Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. <i>Haematologica</i> , 2009, 94, 1563-1568.	3.5	131
4	SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study. <i>British Journal of Haematology</i> , 2014, 166, 98-108.	2.5	110
5	Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. <i>Cancer Research</i> , 2002, 62, 4398-405.	0.9	92
6	The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. <i>European Journal of Cancer</i> , 2009, 45, 1510-1517.	2.8	79
7	Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 14252-14257.	7.1	68
8	SOX11 expression correlates to promoter methylation and regulates tumor growth in hematopoietic malignancies. <i>Molecular Cancer</i> , 2010, 9, 187.	19.2	61
9	High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. <i>Blood</i> , 2005, 105, 2908-2915.	1.4	54
10	The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation. <i>BMC Cancer</i> , 2011, 11, 405.	2.6	48
11	miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator. <i>Blood</i> , 2015, 125, 2669-2677.	1.4	44
12	Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells. <i>American Journal of Hematology</i> , 2009, 84, 803-808.	4.1	41
13	Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference. <i>Blood</i> , 2008, 111, 1617-1624.	1.4	40
14	Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. <i>International Journal of Cancer</i> , 2006, 118, 2092-2097.	5.1	35
15	From Gene Expression Analysis to Tissue Microarrays. <i>Molecular and Cellular Proteomics</i> , 2006, 5, 1072-1081.	3.8	34
16	p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2020, 191, 796-805.	2.5	31
17	Knockdown of SOX11 induces autotaxin-dependent increase in proliferation <i>in vitro</i> and more aggressive tumors <i>in vivo</i> . <i>Molecular Oncology</i> , 2011, 5, 527-537.	4.6	30
18	Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. <i>Blood Advances</i> , 2017, 1, 2257-2268.	5.2	25

#	ARTICLE	IF	CITATIONS
19	Integrated epigenomic and transcriptomic analysis reveals <i>TP63</i> as a novel player in clinically aggressive chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2019, 144, 2695-2706.	5.1	24
20	Expanded clinical and experimental use of SOX11 - using a monoclonal antibody. <i>BMC Cancer</i> , 2012, 12, 269.	2.6	23
21	B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule. <i>Cancer Letters</i> , 2008, 259, 138-145.	7.2	22
22	Increased expression of Ki-67 in mantle cell lymphoma is associated with de-regulation of several cell cycle regulatory components, as identified by global gene expression analysis. <i>Haematologica</i> , 2004, 89, 686-95.	3.5	21
23	Transcriptional profiling and assessment of cell lines as in vitro models for mantle cell lymphoma. <i>Leukemia Research</i> , 2005, 29, 205-213.	0.8	17
24	Protein Expression Profiling of Formalin-Fixed Paraffin-Embedded Tissue Using Recombinant Antibody Microarrays. <i>Journal of Proteome Research</i> , 2013, 12, 5943-5953.	3.7	16
25	SOX11 and HIG-2 are cross-regulated and affect growth in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1883-1892.	1.3	15
26	Definition of Genetic Events Directing the Development of Distinct Types of Brain Tumors from Postnatal Neural Stem/Progenitor Cells. <i>Cancer Research</i> , 2012, 72, 3381-3392.	0.9	14
27	DNA methylation and histone modifications regulate SOX11 expression in lymphoid and solid cancer cells. <i>BMC Cancer</i> , 2015, 15, 273.	2.6	14
28	Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide. <i>Experimental Hematology and Oncology</i> , 2019, 8, 16.	5.0	13
29	CRIM1 is localized to the podocyte filtration slit diaphragm of the adult human kidney. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2038-2044.	0.7	12
30	Infiltration of CD163 ⁺ , PD-L1 ⁺ and FoxP3 ⁺ positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors. <i>British Journal of Haematology</i> , 2021, 193, 520-531.	2.5	12
31	Surrogate antigens as targets for proteome-wide binder selection. <i>New Biotechnology</i> , 2011, 28, 302-311.	4.4	11
32	Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials. <i>Leukemia</i> , 2022, 36, 177-188.	7.2	11
33	Profiling of internalizing tumor-associated antigens on breast and pancreatic cancer cells by reversed genomics. <i>Cancer Letters</i> , 2004, 208, 235-242.	7.2	10
34	Parallel Gene Expression Profiling of Mantle Cell Lymphoma – How Do We Transform ‘Omics Data into Clinical Practice. <i>Current Genomics</i> , 2007, 8, 171-179.	1.6	7
35	Identification of uniquely expressed transcription factors in highly purified B cell lymphoma samples. <i>American Journal of Hematology</i> , 2010, 85, 418-425.	4.1	7
36	Identification of V-ATPase as a molecular sensor of SOX11-levels and potential therapeutic target for mantle cell lymphoma. <i>BMC Cancer</i> , 2016, 16, 493.	2.6	4

#	ARTICLE	IF	CITATIONS
37	Frequency and clinical implications of SOX11 expression in Burkitt lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 1760-1763.	1.3	4
38	Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF- κ B activity. <i>BMC Cancer</i> , 2018, 18, 466.	2.6	4
39	Kalirin-RAC controls nucleokinetic migration in ADRN-type neuroblastoma. <i>Life Science Alliance</i> , 2021, 4, e201900332.	2.8	4
40	Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk. <i>BMC Cancer</i> , 2020, 20, 1202.	2.6	3
41	Nuclear T-STAR Protein Expression Correlates with HER2 Status, Hormone Receptor Negativity and Prolonged Recurrence Free Survival in Primary Breast Cancer and Decreased Cancer Cell Growth In Vitro. <i>PLoS ONE</i> , 2013, 8, e70596.	2.5	2
42	Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets. <i>Leukemia and Lymphoma</i> , 2021, 62, 2637-2647.	1.3	2
43	Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma. <i>Cancer Reports</i> , 2021, , e1524.	1.4	1
44	Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 655-666.	2.8	1
45	Emerging role of SOX11 in mantle cell lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2015, , 35.	2.7	0